Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Gastroenterol ; 11: 27, 2011 Mar 24.
Article in English | MEDLINE | ID: mdl-21435225

ABSTRACT

BACKGROUND: Well differentiated neuroendocrine tumours (carcinoids), arising from cells of the diffuse neuroendocrine system, represent the most commonly encountered gastric endocrine tumours. Gastrointestinal stromal tumours (GISTs), which stem from interstitial Cajal cells located within the wall of the gastrointestinal tract and have a characteristic immunoreactivity for CD117 (c-kit protein), account for the majority of gastrointestinal mesenchymal neoplasms. Simultaneous occurrence of a GIST with a well differentiated neuroendocrine tumour in the stomach is very rare. METHODS: Clinical history, endoscopy and histopathological findings were utilized for our diagnostic considerations. RESULTS: We report the coexistence of a high risk GIST with a well differentiated neuroendocrine tumour of benign clinical behavior, both located in the stomach, in a 62-year-old man previously operated for a gastric well differentiated neuroendocrine tumour with uncertain malignant behaviour. CONCLUSIONS: Even single well differentiated, sporadic, NETs of small size may coexist with GISTs. An appropriate initial therapeutic approach combined with a scrupulous follow-up seems to play a significant role in terms of preventing a metastatic disease.


Subject(s)
Gastrointestinal Stromal Tumors/diagnosis , Neoplasms, Multiple Primary/diagnosis , Neuroendocrine Tumors/diagnosis , Stomach Neoplasms/diagnosis , Antineoplastic Agents/therapeutic use , Benzamides , Biomarkers, Tumor/metabolism , Combined Modality Therapy , Gastrointestinal Stromal Tumors/metabolism , Gastrointestinal Stromal Tumors/therapy , Gastroscopy , Humans , Imatinib Mesylate , Male , Middle Aged , Neoplasms, Multiple Primary/metabolism , Neoplasms, Multiple Primary/therapy , Neuroendocrine Tumors/metabolism , Neuroendocrine Tumors/therapy , Piperazines/therapeutic use , Proto-Oncogene Proteins c-kit/metabolism , Pyrimidines/therapeutic use , Stomach Neoplasms/metabolism , Stomach Neoplasms/therapy , Treatment Outcome
2.
Atherosclerosis ; 208(1): 3-9, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19595353

ABSTRACT

Coronary heart disease (CHD) is a leading cause of death in western societies. In the last few decades, a number of epidemiological studies have shown that a disproportion between atheroprotective and atherogenic lipoproteins in plasma is one of the most important contributors towards atherosclerosis and CHD. Thus, based on the classical view, reduced HDL cholesterol levels independently predict one's risk factor for developing cardiovascular disease, while elevated HDL levels protect from atherosclerosis. However, more recent studies have suggested that the relationship between HDL and cardiovascular risk is more complex and extends beyond the levels of HDL in plasma. These studies challenge the existing view on HDL and cardiovascular risk and trigger a discussion as to whether low HDL is a causal effect for the development of heart disease. In this article we provide a review of the current literature on the biogenesis of HDL and its proposed functions in atheroprotection. In addition, we discuss the significance of both HDL quality and quantity in assessing cardiovascular risk.


Subject(s)
Atherosclerosis/metabolism , Lipoproteins, HDL/biosynthesis , Atherosclerosis/complications , Coronary Disease/etiology , Humans , Lipoproteins, HDL/physiology
3.
FEBS J ; 276(20): 5720-8, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19754875

ABSTRACT

Apolipoprotein E is a polymorphic glycoprotein in humans with a molecular mass of 34.5 kDa. It is a component of chylomicron remnants, very low density lipoprotein, low density lipoprotein and high density lipoprotein, and is primarily responsible for maintaining plasma lipid homeostasis. In addition to these well-documented functions, recent studies in experimental mouse models, as well as population studies, show that apolipoprotein E also plays an important role in the development of obesity and insulin resistance. It is widely accepted that disruption in homeostasis between food intake and energy expenditure, and the subsequent deposition of excess fatty acids into fat cells in the form of triglycerides, leads to the development of obesity. Despite the pivotal role of obesity and dyslipidemia in the development of the metabolic syndrome and heart disease, the functional interactions between adipose tissue and components of the lipoprotein transport system have not yet been investigated thoroughly. In this minireview, we focus on the current literature pertinent to the involvement of apolipoprotein E in the development of pathologies associated with the metabolic syndrome.


Subject(s)
Apolipoproteins E/physiology , Obesity/metabolism , Obesity/pathology , Animals , Apolipoproteins E/genetics , Apolipoproteins E/metabolism , Humans , Insulin Resistance/genetics , Insulin Resistance/physiology , Mice , Obesity/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...